Historical Stock Chart
2 Months : From Sep 2019 to Nov 2019
By Adria Calatayud
Shares in NetScientific PLC (NSCI.LN) rose Thursday after it said portfolio company PDS Biotechnology Corp. (PDSB) will collaborate with U.S. drug maker Merck & Co. Inc. (MRK) in a phase II clinical trial.
NetScientific, a London-based healthcare technology company, said the trial will study PDS's lead product, PDS0101, in combination with Merck's cancer drug Keytruda as a first line treatment in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 infection.
Shares in NetScientific at 1256 GMT were up 40% at 8.75 pence.
Write to Adria Calatayud at firstname.lastname@example.org
(END) Dow Jones Newswires
October 03, 2019 09:13 ET (13:13 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.